PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10365914-7	1999	Analysis of the IGF-1 receptor (IGF-1r) and epidermal growth factor (EGFr) in the epidermis of TPA-treated HK1.IGF-1 transgenic and non-transgenic mice revealed that both receptors were activated (hyperphosphorylated on tyrosine residues), and the level of activation was higher in transgenic mice.	Tetradecanoylphorbol Acetate	95-98	insulin-like growth factor 1	Mus musculus	16-21	
18483250-6	2008	Western blot analyses of epidermal extracts revealed reduced activation of both the epidermal growth factor and IGF-I receptors in response to TPA treatment in LID mice.	Tetradecanoylphorbol Acetate	143-146	insulin-like growth factor 1	Mus musculus	112-117	
16368122-6	2006	Arsenic/TPA also decreased the expression of BRCA1, betaine-homocysteine methyltransferase, CYP7B1, CYP2F2 and insulin-like growth factor-1 in normal and cancerous livers.	Tetradecanoylphorbol Acetate	8-11	insulin-like growth factor 1	Mus musculus	111-139	
10749124-6	2000	Treatment of BK5.IGF-1 transgenic mice with multiple topical applications of the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate, in the absence of tumor initiation led to the development of additional skin papillomas.	Tetradecanoylphorbol Acetate	96-132	insulin-like growth factor 1	Mus musculus	17-22	
16338928-8	2006	TPA also attenuated IGF-1 and epidermal growth factor-induced phospho-Ser-473-Akt, reduced Akt kinase activity, and blocked IGF-1 protection from UVC-induced apoptosis.	Tetradecanoylphorbol Acetate	0-3	insulin-like growth factor 1	Mus musculus	20-25	
16338928-8	2006	TPA also attenuated IGF-1 and epidermal growth factor-induced phospho-Ser-473-Akt, reduced Akt kinase activity, and blocked IGF-1 protection from UVC-induced apoptosis.	Tetradecanoylphorbol Acetate	0-3	insulin-like growth factor 1	Mus musculus	124-129	
10365914-3	1999	HK1.IGF1 transgenic mice, which overexpress IGF-1 in epidermis via the human keratin 1 promoter, were previously shown to be hypersensitive to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA).	Tetradecanoylphorbol Acetate	167-203	insulin-like growth factor 1	Mus musculus	4-8	
10365914-3	1999	HK1.IGF1 transgenic mice, which overexpress IGF-1 in epidermis via the human keratin 1 promoter, were previously shown to be hypersensitive to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA).	Tetradecanoylphorbol Acetate	167-203	insulin-like growth factor 1	Mus musculus	44-49	
10365914-3	1999	HK1.IGF1 transgenic mice, which overexpress IGF-1 in epidermis via the human keratin 1 promoter, were previously shown to be hypersensitive to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA).	Tetradecanoylphorbol Acetate	205-208	insulin-like growth factor 1	Mus musculus	4-8	
9135074-6	1997	Adult HK1.IGF-1 mice developed spontaneous tumors following treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) alone and exhibited an exaggerated epidermal proliferative response following treatment with the tumor promoter compared to non transgenic littermates.	Tetradecanoylphorbol Acetate	75-111	insulin-like growth factor 1	Mus musculus	10-15	
10365914-3	1999	HK1.IGF1 transgenic mice, which overexpress IGF-1 in epidermis via the human keratin 1 promoter, were previously shown to be hypersensitive to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA).	Tetradecanoylphorbol Acetate	205-208	insulin-like growth factor 1	Mus musculus	44-49	
9135074-6	1997	Adult HK1.IGF-1 mice developed spontaneous tumors following treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) alone and exhibited an exaggerated epidermal proliferative response following treatment with the tumor promoter compared to non transgenic littermates.	Tetradecanoylphorbol Acetate	113-116	insulin-like growth factor 1	Mus musculus	10-15	
7510294-2	1994	12-O-Tetradecanoylphorbol-13-acetate (TPA), an activator of protein kinase C, decreased the secretion of immunoreactive IGF-I into the medium, whereas dibutyryl cAMP (Bt2cAMP) augmented the secretion.	Tetradecanoylphorbol Acetate	0-36	insulin-like growth factor 1	Mus musculus	120-125	
7510294-2	1994	12-O-Tetradecanoylphorbol-13-acetate (TPA), an activator of protein kinase C, decreased the secretion of immunoreactive IGF-I into the medium, whereas dibutyryl cAMP (Bt2cAMP) augmented the secretion.	Tetradecanoylphorbol Acetate	38-41	insulin-like growth factor 1	Mus musculus	120-125	
1472895-4	1992	The PKC activator, 12-O-tetradecanoylphorbol-13-acetate (TPA) suppressed IGF-I secretion in a dose-dependent manner.	Tetradecanoylphorbol Acetate	19-55	insulin-like growth factor 1	Mus musculus	73-78	
1472895-4	1992	The PKC activator, 12-O-tetradecanoylphorbol-13-acetate (TPA) suppressed IGF-I secretion in a dose-dependent manner.	Tetradecanoylphorbol Acetate	57-60	insulin-like growth factor 1	Mus musculus	73-78	
1472895-10	1992	Exogenous IGF-I recovered the inhibitory effect of TPA on 45Ca-accumulation.	Tetradecanoylphorbol Acetate	51-54	insulin-like growth factor 1	Mus musculus	10-15	
2120207-9	1990	The TPA-induced reduction of [3H]phosphatidylcholine was completely blocked by 50 microM sphingosine and 50 microM H-7, inhibitors of protein kinase C. Both sphingosine and H-7 attenuated IGF-I-mediated reduction of [3H]phosphatidylcholine.	Tetradecanoylphorbol Acetate	4-7	insulin-like growth factor 1	Mus musculus	188-193